Terazosin Capsule
Product Images NDC 69452-332

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 69452-332). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bionpharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Figure 01)

Figure 1 from Study 1 presents two line graphs comparing placebo and Terazosin. The left graph shows mean change in total symptom score from baseline over 3 months, with Terazosin showing greater symptom score reduction than placebo. The right graph shows mean increase in peak flow rate (mL/sec) from baseline over 3 months, with Terazosin demonstrating a larger increase compared to placebo. Both graphs include error bars and sample sizes (N).*

FDA Label Image

Image Description (Figure 02)

A line graph titled "Mean Change in Total Symptom Score from Baseline Long-Term, Open-Label, Non-Placebo Controlled Study (N=494)" showing mean change from baseline on the y-axis (ranging from 0 to -7) and time in months on the x-axis (0 to 30). The graph depicts a steady decrease in symptom score over time, leveling off after month 3, with data points marked at various months and some marked with asterisks.*

FDA Label Image

Image Description (Figure 03)

Line graph depicting the mean change in peak flow rate from baseline over a 30-month period during a long-term, open-label, non-placebo controlled study with 494 participants. The y-axis shows mean change in mL/sec and the x-axis represents months, indicating a general trend of increase with several points marked for statistical significance.*

FDA Label Image

Image Description (Image001)

Terazosin Capsules, USP 1 mg oral capsule label showing quantity of 100 capsules. The label includes manufacturer Bionpharma Inc., storage instructions, barcode, and product identification details including NDC and lot/expiration placeholders. The label specifies the active ingredient as Terazosin hydrochloride equivalent to 1 mg terazosin.*

FDA Label Image

Image Description (Image002)

Label for Terazosin Capsules, USP 2 mg by Bionpharma Inc. The label states the capsules contain Terazosin hydrochloride equivalent to 2 mg of terazosin. The package includes 100 oral capsules and indicates storage and handling instructions. Manufactured in India and distributed by Bionpharma Inc., Princeton, NJ.*

FDA Label Image

Image Description (Image003)

Label for Terazosin Capsules, USP 5 mg oral capsules by Bionpharma Inc. The label states the product contains 100 capsules per container and includes storage instructions, a barcode, and batch information. The capsules contain terazosin hydrochloride equivalent to 5 mg terazosin each.*

FDA Label Image

Image Description (Image004)

Label of Terazosin Capsules, USP 10 mg oral capsules by Bionpharma Inc. The label indicates 100 capsules in the container, with storage instructions and dosage details. The product is for prescription use only and is distributed by Bionpharma Inc., Princeton, NJ. The label includes the NDC number 69452-333-20.*

FDA Label Image

Image Description (Structure001)

Chemical structure diagram of Terazosin, showing its molecular framework including aromatic rings and functional groups associated with the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.